Healthcare & Pharmaceuticals News
More newsCompounded GLP-1 medicines under sustained scrutiny in South Africa as SAHPRA and SAPC take enforcement action
South Africa’s regulatory stance on compounded Glucagon-like peptide 1 (GLP-1) medicines has moved from warning signals to visible enforcement. On 23 May 2026, the South African Health Products Regulatory Authority (SAHPRA), together with the South African Pharmacy Council (SAPC), announced intensified enforcement action against the unlawful manufacturing and distribution of unregistered GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) medicines containing semaglutide, tirzepatide or a combination of both, promoted for weight loss.
Legal, clinical and commercial risk associated with GLP-1 drugs
Charles Green, Senior Associate in the Healthcare & Pharmaceuticals sector, recently joined Jeremy Maggs on Hot FM to discuss the legal, clinical, and commercial risks associated with compounded GLP-1 drugs.
Global trends around compounded GLP 1 medicines and SAHPRA’s emerging response
Compounded Glucagon-like peptide 1 (GLP 1) medicines have surged worldwide as demand for weight loss and diabetes treatments continues to outstrip supply. These compounded versions often include modified formulations and added vitamins, or are manufactured outside regulated supply chains, making them significantly different from approved registered products.